VOL. 25 · NO. 2 | May 2010
 
VIEW ALL ABSTRACTS +
Frontmatter
Statist. Sci. 25 (2), (May 2010)
No abstract available
Statist. Sci. 25 (2), (May 2010)
No abstract available
Articles
Bradley Efron
Statist. Sci. 25 (2), 145-157, (May 2010) DOI: 10.1214/09-STS308
KEYWORDS: Statistical learning, experience of others, Bayesian and frequentist, James–Stein, Benjamini–Hochberg, False discovery rates, effect size
Sander Greenland
Statist. Sci. 25 (2), 158-161, (May 2010) DOI: 10.1214/10-STS308A
No abstract available
Andrew Gelman
Statist. Sci. 25 (2), 162-165, (May 2010) DOI: 10.1214/10-STS308B
No abstract available
Robert E. Kass
Statist. Sci. 25 (2), 166-169, (May 2010) DOI: 10.1214/10-STS308C
KEYWORDS: Bayesian, decision theory, prior information, statistical pragmatism, statistical science
Bradley Efron
Statist. Sci. 25 (2), 170-171, (May 2010) DOI: 10.1214/10-STS308REJ
No abstract available
Chris Sherlock, Paul Fearnhead, Gareth O. Roberts
Statist. Sci. 25 (2), 172-190, (May 2010) DOI: 10.1214/10-STS327
KEYWORDS: Random walk Metropolis, Metropolis–Hastings, MCMC, adaptive MCMC, MMPP
Ying Kuen Cheung
Statist. Sci. 25 (2), 191-201, (May 2010) DOI: 10.1214/10-STS334
KEYWORDS: Coherence, dichotomized data, discrete barrier, ethics, indifference interval, maximum likelihood recursion, unbiasedness, virtual observations
John O’Quigley, Mark Conaway
Statist. Sci. 25 (2), 202-216, (May 2010) DOI: 10.1214/10-STS332
KEYWORDS: Bayesian methods, clinical trial, continual reassessment method, dose escalation, dose-finding studies, efficacy, maximum likelihood, maximum tolerated dose, most successful dose, Phase 1 trials, Phase 2 trials, toxicity
Mourad Tighiouart, André Rogatko
Statist. Sci. 25 (2), 217-226, (May 2010) DOI: 10.1214/10-STS333
KEYWORDS: Cancer phase I trials, dose-limiting toxicity, escalation with overdose control, tolerated dose, optimal Bayesian feasible
Peter F. Thall
Statist. Sci. 25 (2), 227-244, (May 2010) DOI: 10.1214/09-STS315
KEYWORDS: adaptive design, Bayesian design, clinical trial, dose-finding, phase I trial, phase I/II trial
Jay Bartroff, Tze Leung Lai
Statist. Sci. 25 (2), 245-257, (May 2010) DOI: 10.1214/10-STS317
KEYWORDS: dynamic programming, maximum tolerated dose, Monte Carlo, rollout, stochastic optimization
Christian Genest, Gordon Brackstone
Statist. Sci. 25 (2), 258-273, (May 2010) DOI: 10.1214/08-STS272
KEYWORDS: AT&T, Canadian census, probability plots, Shapiro–Wilk statistic, Statistical Society of Canada, Statistics Canada
Back to Top